Drug Search Results
More Filters [+]

Decernotinib

Alternative Names: decernotinib, vx-509
Latest Update: 2024-02-26
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: JAK1 Inhibitor,JAK2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Vertex
Company Location: BOSTON MA 02210
Company CEO: Reshma Kewalramani
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Decernotinib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Arthritis, Rheumatoid

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2011-004419-22

P2

Completed

Arthritis, Rheumatoid

2014-07-31

2012-004342-14

P3

Terminated

Arthritis, Rheumatoid

2014-07-28

VX11-509-102

P2

Completed

Arthritis, Rheumatoid

2014-07-01

VX12-509-104

P3

Completed

Arthritis, Rheumatoid

2014-07-01

Recent News Events